Biomarcadores por tomografia por emisión de positrones (PET): imagen de la patología de Alzheimer y la neurodegeneración al servicio del diagnóstico clínico

García‐Ribas, Guillermo; Arbizu, Javier; Carrió, Ignasi; Garrastachu, Puy; Martínez-Lage, Pablo

doi:10.1016/j.nrl.2016.03.002

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In these cases, PET imaging might support or exclude the clinically suspected etiology avoiding the unnecessary use of costly and potentially harmful treatments and allowing a rapid and accurate diagnosis. This has important positive impacts on the patient, his family and society [158].…”

Section: Petmentioning

confidence: 99%

Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights

Clara

Lavitrano

Salvatore

et al. 2020

JPM

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common neurodegenerative disease among the elderly, affecting millions of people worldwide and clinically characterized by a progressive and irreversible cognitive decline. The rapid increase in the incidence of AD highlights the need for an easy, efficient and accurate diagnosis of the disease in its initial stages in order to halt or delay the progression. The currently used diagnostic methods rely on measures of amyloid-β (Aβ), phosphorylated (p-tau) and total tau (t-tau) protein levels in the cerebrospinal fluid (CSF) aided by advanced neuroimaging techniques like positron emission tomography (PET) and magnetic resonance imaging (MRI). However, the invasiveness of these procedures and the high cost restrict their utilization. Hence, biomarkers from biological fluids obtained using non-invasive methods and novel neuroimaging approaches provide an attractive alternative for the early diagnosis of AD. Such biomarkers may also be helpful for better understanding of the molecular mechanisms underlying the disease, allowing differential diagnosis or at least prolonging the pre-symptomatic stage in patients suffering from AD. Herein, we discuss the advantages and limits of the conventional biomarkers as well as recent promising candidates from alternative body fluids and new imaging techniques.

show abstract

Section: Petmentioning

confidence: 99%

Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights

Clara

Lavitrano

Salvatore

et al. 2020

JPM

View full text Add to dashboard Cite

show abstract

“…La agregación extracelular de la proteína ␤ amiloidea y la tau hiperfosforilada en la degeneración neurofibrilar en las neuronas son las alteraciones neuropatológicas características de la enfermedad de Alzheimer (EA), las cuales pueden identificarse directamente en los pacientes a través de la marcación amiloidea de una PET cerebral 1,2 o indirectamente con la reducción del nivel de la A␤ 1-42 , y el aumento de la tau total y la tau fosforilada en líquido cefalorraquídeo (LCR) 3 . Basados en el uso de estos biomarcadores en el National Institute of Aging and Alzheimer's Association (Instituto Nacional de Envejecimiento y la Asociación de Alzheimer [NIA-AA]) generaron recomendaciones para el diagnóstico de deterioro cognitivo leve (DCL) debido a EA 4 y Alzheimer presintomático 5 .…”

Section: Introductionunclassified

Biomarcadores de enfermedad de Alzheimer en deterioro cognitivo leve: experiencia en una clínica de memoria de Latinoamérica

et al. 2021

View full text Add to dashboard Cite

show abstract

Biomarkers of Alzheimer disease in mild cognitive impairment: Experience in a memory clinic from Latin America

Allegri

Méndez

Russo

et al. 2021

Neurología (English Edition)

View full text Add to dashboard Cite

Biomarcadores por tomografia por emisión de positrones (PET): imagen de la patología de Alzheimer y la neurodegeneración al servicio del diagnóstico clínico

Cited by 4 publications

References 5 publications

Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights

Molecular and Imaging Biomarkers in Alzheimer’s Disease: A Focus on Recent Insights

Biomarcadores de enfermedad de Alzheimer en deterioro cognitivo leve: experiencia en una clínica de memoria de Latinoamérica

Biomarkers of Alzheimer disease in mild cognitive impairment: Experience in a memory clinic from Latin America

Contact Info

Product

Resources

About